Latest news
AstraZeneca’s trastuzumab deruxtecan gets additional approval in India for HER2-positive early breast cancer - Indian Pharma PostIndian Pharma Post · Sat, 08 Aug 2026 14:11:09 GMTAstraZeneca Pharma gets CDSCO nod to market Enhertu for additional indication - Business StandardBusiness Standard · Sat, 08 Aug 2026 12:20:02 GMTAstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer - NDTV ProfitNDTV Profit · Sat, 08 Aug 2026 09:00:27 GMTAstraZeneca Pharma India secures CDSCO approval for Enhertu in new breast cancer use - scanx.tradescanx.trade · Sat, 08 Aug 2026 06:31:12 GMTAstraZeneca Pharma India Limited Revenue Breakdown – NSE:ASTRAZEN - TradingViewTradingView · Tue, 28 Jul 2026 11:51:15 GMTAstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug - CNBC TV18CNBC TV18 · Tue, 28 Jul 2026 11:17:19 GMTAstraZeneca Pharma India receives CDSCO approval for HER2-positive stage II or III early breast cancer treatment - BioSpectrum IndiaBioSpectrum India · Tue, 28 Jul 2026 07:00:00 GMTAstraZeneca Pharma receives ₹79.97 lakh NPPA demand for overcharging - scanx.tradescanx.trade · Tue, 28 Jul 2026 07:00:00 GMT